Boston Scientific (BSX) Q3 2026 Earnings Call Transcript
Boston Scientific (BSX) reported Q3 2026 organic sales growth of 1.5%, missing guidance due to a cybersecurity incident. Q3 adjusted EPS was $0.73, down 3% from guidance. Q4 is expected to see a 1-3% revenue decline and EPS of $0.77-$0.79. Full-year 2026 revenue growth is guided at 4%, with EPS of $3.16-$3.18. The company anticipates challenges in 2027 but plans for growth in 2028-2029, driven by new launches and market expansions.
How this was made
The 30-second read
Why it matters
The disclosed lower guidance and cyber‑incident impact suggest near‑term downside, but the company highlights restructuring and upcoming product launches for longer‑term growth.
Market read
Earnings and guidance update for a large‑cap med‑tech firm, with immediate price implications.
What to watch
Long‑term pipeline of new product launches and $25 bn market opportunity by 2030 could offset short‑term headwinds.
Background
Boston Scientific held its Q3 2026 earnings call, providing results and outlook for the remainder of the year.
Ticker impact
Q3 adjusted EPS $0.73 and organic sales +1.5% disclosed, with FY 2026 guidance lowered to 4% revenue growth and $3.16‑$3.18 EPS.
downward pressure as investors price in lower revenue growth and cyber‑related headwinds
Guidance below prior expectations and a disclosed cyber incident reducing sales growth by ~300 bps create near‑term downside risk.
Market effects
Medical‑device sector may see broader pressure from cyber‑risk concerns and slower growth guidance.
US med‑tech stocks could face modest pullback in early trading.
International investors in med‑tech may adjust exposure based on the guidance and cyber‑incident fallout.
Counterpoint
If the cyber‑incident is resolved quickly, the company could rebound and exceed guidance, offering upside.
Key entities
- CompanyBoston Scientific
Medical‑device maker reporting Q3 results and FY guidance.
- CompanyPenumbra
Target of a pending acquisition by Boston Scientific.
